Registration Dossier

Administrative data

Key value for chemical safety assessment

Effects on fertility

Effect on fertility: via oral route
Endpoint conclusion:
no study available (further information necessary)
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available

Effects on developmental toxicity

Description of key information

Treatment with t-dodecyl mercaptan by whole body inhalation at an actual exposure level of 88.6 ppm (776.6 mg/m3) or less did not produce a teratogenic effect in mice or rats.

In a study similar to OECD TG 414 (Scherdein, 1983a), 25 pregnant Sprague-Dawley rats/concentration were exposed (inhalation; whole body) to t-dodecyl mercaptan at analyzed concentrations of 22.6 (0.19 mg/L) and 88.6 ppm (0.73 mg/L) for 6 hours/day during GD 6-19. One female died at the 88.6 ppm concentration level and the cause of death was undetermined. There were no test substance-related body weight changes. Also, there were no test substance-related fetal malformations. The NOAEC for maternal toxicity developmental toxicity was 88.6 ppm (0.73 mg/L) (highest exposure concentration tested). 

 

A second study (Scherdein, 1983b) was conducted with 25 CD-1 female mice/concentration at the same concentrations as the above rat study, with exposure for 6 hours/day during GD 6-16. One mouse died at the 22.6 ppm (0.19 mg/L) level, and the cause of death was unknown. There were no test substance-related changes in body weights. There were no statistically significant test substance-related fetal malformations noted. The mean number of total implants, corpora lutea, fetal body weight and sex ratio were unaffected by exposure to the test substance. It should be noted that 3/25 control mice and 5/25 mice from each exposure concentration exhibited total implant resorption; the incidence of resorptions was not considered to be related to test substance. The NOAEC for maternal and developmental toxicity was 88.6 ppm (0.73 mg/L) (highest exposure concentration tested)

Link to relevant study records

Referenceopen allclose all

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Meets generally accepted scientific standards, well documented and acceptable for assessment
Qualifier:
equivalent or similar to
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Deviations:
yes
Remarks:
only two concentration tested
GLP compliance:
yes
Limit test:
no
Species:
rat
Strain:
Sprague-Dawley
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Charles River Breeding Laboratories, Inc., Portage, Michigan
- Age at study initiation: 12 weeks old
- Weight at study initiation: 205 and 264 grams on gestation day 0
- Fasting period before study: no
- Housing: individually in hanging wire-mesh cages, nn gestation day 6 animals were transferred to stainless steel and glass exposure chambers
- Diet (ad libitum, except during the exposure period ): Purina® Certified Rodent Chow® #5002
- Water (ad libitum, except during the exposure period): tap water
- Acclimation period: 14 day

ENVIRONMENTAL CONDITIONS
- Temperature (°F): 76-85 (exposure chambers)
- Humidity (%): 35-41 (exposure chambers)
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12
Route of administration:
inhalation: vapour
Type of inhalation exposure (if applicable):
whole body
Vehicle:
air
Details on exposure:
GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: stainless steel and glass exposure chambers with a volume of one cubic meter
- Method of holding animals in test chamber: individually in hanging wire-mesh cages
- System of generating vapor: Vapor atmospheres of t-dodecyl mercaptan (TDM) were generated by one of two methods. The first method was used to generate the 25 ppm group atmosphere. With this system a syringe-drive pump (Sage model 355) delivered the test materiai at a known, constant rate to the top of a 19.6 cm high column filled with 5 mm diameter glass beads. Air heated by a 400 watt cartridge heater passed up the bead column counter-current to the liquid flow. Vaporization occurred within the bead column. The vapors were then piped to the air inlet of the exposure chamber where dilution with chamber ventilation air (approximately 250 L/min) reduced the concentration to the desired level. Heat tape was wrapped around the trap to prevent condensation. The current supplied to both the cartridge heater and the heat tape was controlled individually by variable autotransformers.
The TDM concentration for the 100 ppm group was generated with a second method of vapor generation. With this system all of the chamber ventilation air was passed through an atomization chamber which had been charged with a known amount of test material. An FMI laboratory pump was then used to deliver the test material to an atomizer (Spraying Systems, No. 1650 liquid nozzle, No. 64 air nozzle). The atomization step served to greatly increase the surface area of the test material which increased, in turn, the vaporization rate to obtain a relatively high vapor concentration of test material. Glass wool was placed in the exit pipe of the atomization chamber to prevent aerosol from passing into the exposure chamber. To overcome the resistance of the glass wool filter, the exposure chamber was operated at a negative pressure of approximately 0.2 - 0.4 inches of vater.
- Temperature, humidity, pressure in air chamber: 76-85 °F, 35-41%
- Air flow rate: no data
- Air change rate: no data
- Method of particle size determination: Since the generation method for the 100 ppm group vapor level involved an atomization step, samples were collected to determine the amount of aerosol in the chamber atmosphere. Samples were collected on 25 mm glass fiber filters at a rate of 1 L/min for 30 minutes. The filters were placed in 2 ml of n-hexane to extract the collected TDM and 2 pl of the resultant solution were injected into the GC. Two injections were made of each of 4 filter samples. Three concurrent vapor samples were collected for each filter sample. During the experiment the vapor phase concentration averaged 53 ppm while the samples of recovered aerosol averaged 0.18 ppm. From these data we concluded that aerosol would not constitute an appreciable fraction of the total TDM concentration in the vapor exposure atmosphere.
- Treatment of exhaust air: no data

TEST ATMOSPHERE
- Brief description of analytical method used: The actual vapor concentration of TDM in the chamber atmosphere was determined by a gas chromatograph fitted with a gas sampling valve and sample loop. The GC was connected to a Hewlett-Packard Model 3388A integrator for data collection and reduction and was calibrated with liquid-phase standards of TDM in n-hexane.
- Samples taken from breathing zone: yes
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
see above
Details on mating procedure:
At the end of the acclimation period, all animals were weighed and subjected to a detailed physical examination. At this time, animals considered suitable for study were cohabitated with stock males utilized exclusively for this purpose.
One female and one male animal of the same species, strain and source were placed together for mating. The occurrence of copulation was determined by daily inspection for a copulatory plug or vaginal smear for sperm. The day evidence of mating was detected was
designated day 0 of gestation and the female was returned to an individual cage, assigned a permanent animal number and properly identified by ear-tag.
Duration of treatment / exposure:
G6 to G19
Frequency of treatment:
6 hours/day
Duration of test:
up to gestation day 20
Dose / conc.:
22.7 ppm (analytical)
Remarks:
Target conc.: 25 ppm
Dose / conc.:
88.6 ppm (analytical)
Remarks:
Target conc.: 100 ppm
No. of animals per sex per dose:
25
Control animals:
yes, sham-exposed
Details on study design:
- Dose selection rationale:
- Rationale for animal assignment (if not random): Mated females were consecutively assigned in a block design to one control group and two t-dodecyl mercaptan treated groups of 25 rats. The order in which the mated females were assigned corresponded to the day the copulatory plug was observed and the order in which the animal appeared on the breeding record. The first mated female on the breeding record was assigned to the first group. The second mated female was assigned to the next group. Animals were assigned in this manner until the required number of mated females had been placed into each group.
Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Prior to treatment, the females were observed twice daily for mortality and overt changes in appearance and behavior. They were observed twice daily for mortality and once daily for clinical signs of toxicity from gestation day 6 through sacrifice. Females not surviving to the scheduled sacrifice were necropsied in an attempt to determine the cause of death.

DETAILED CLINICAL OBSERVATIONS: No

BODY WEIGHT: Yes
- Time schedule for examinations: gestation days 0, 6, 9, 12, 16 and 20

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): No

POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: On gestation day 20 all surviving dams were sacrificed by carbon dioxine inhalation. The abdominal and thoracic cavities and organs of the dams were examined for grossly evident morphological changes and the carcasses discarded.
Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: number and location of viable and nonviable fetuses
Fetal examinations:
All fetuses were individually weighed and examined for external malformations and variations, including the palate and eyes. Each fetus was externally sexed and individually numbered and tagged for identification. Approximately one-third of the fetuses were placed in Bouin's fixative for subsequent visceral examination by razor-blade sectioning as described by Wilson. The remaining two-thirds of the fetuses were fixed in alcohol, macerated in potassium hydroxide and stained with Alizarin Red S by a method similar to that described by Dawson for subsequent skeletal examination.
Statistics:
The male to female fetal sex distribution and the number of litters with malformations were compared using the Chi-square test criterion with Yates' correction for 2 x 2 contingency tables and/or Fisher's exact probability test as described by Siegel to judge significance of differences.
The number of early and late resorptions, nonviable fetuses and postimplantation loss were compared by the Mann-Whitney U-test as described by Siegel and Weil to judge significance of differences.
The mean number of viable fetuses, total implantations, corpora lutes and mean fetal body weights were compared by analysis of variance (one-way classification), Bartlett's test for homogeneity of variances and the appropriate t-test (for equai or unequal variances) as described by Steel and Torrie using Dunnett's multiple comparison tables to judge significance ot differences.
Clinical signs:
no effects observed
Description (incidence and severity):
There were no biologically meaningful differences in the appearance and behavior of rats in the t-dodecyl mercaptan treated groups when compared to those of the rats in the control group. Incidental observations occurring in a few control and/or treated rats included hair loss, soft stool, reddened conjunctiva, wet red matter or red liquid in the vagins or toes red, swollen and/or scabbed. A circumscribed areas in the inguinal area was noted in a female in the 100 ppm group.
Dermal irritation (if dermal study):
not examined
Mortality:
mortality observed, non-treatment-related
Description (incidence):
One rat in the 100 ppm group died on gestation day 14. Antemortem observations included thinness, an unkempt haircoat and reddened conjunctiva. Mottled kidneys were noted at necropsy; the cause of death could not be determined. The normally developing implants in this female were inadvertently not examined further. Survival was 100% in the control group and the 25 ppm group.
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
There was a dose-related decrease in mean maternal body weight gain of the rats in the treated groups when compared to the control value over the entire exposure period (gestation days 6-20) and the entire gestation period (gestation days 0-20).
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
no effects observed
Description (incidence and severity):
The occurrence of necropsy findings in the 25 ppm and 100 ppm groups was similar to that of the control group. Incidental observations included hydronephrosis, pitted kidneys, calculi in the kidneys, ureters and urinary bladder and distended ureters.
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined
Other effects:
not specified
Number of abortions:
no effects observed
Pre- and post-implantation loss:
no effects observed
Total litter losses by resorption:
no effects observed
Early or late resorptions:
no effects observed
Dead fetuses:
no effects observed
Changes in pregnancy duration:
not examined
Description (incidence and severity):
Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not examined
Changes in number of pregnant:
no effects observed
Other effects:
not specified
Details on maternal toxic effects:
There were no biologically meaningful or statistically significant differences in the mean number of postimplantation loss, total implantations and corpora lutea in the treated groups.
Key result
Dose descriptor:
LOAEC
Effect level:
22.7 ppm (analytical)
Based on:
test mat.
Basis for effect level:
body weight and weight gain
Abnormalities:
effects observed, treatment-related
Description (incidence and severity):
decreases in mean body weight gain
Fetal body weight changes:
effects observed, non-treatment-related
Description (incidence and severity):
A slight (less than 10%) but statistically significant increase in mean fetal body weight in comparison to the control value occurred in the 100 ppm group. The 100 ppm group mean fetal body weight was comparable to the mean value in the historical control data. The mean fetal body weight in the 25 ppm group was similar to that of the control group and the historical control data; no statistically significant differences from the control group were observed.
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): effects observed, non-treatment-related
Reduction in number of live offspring:
no effects observed
Changes in sex ratio:
no effects observed
Changes in litter size and weights:
no effects observed
Changes in postnatal survival:
not examined
External malformations:
no effects observed
Skeletal malformations:
no effects observed
Visceral malformations:
no effects observed
Other effects:
not specified
Details on embryotoxic / teratogenic effects:
The incidence of fetal malformations in litters of the rats in the t-dodecyl mercaptan treated groups was comparable to that of the control group; no statistically significant differences were observed.
There were no biologically meaningful differences in the occurrence of genetic and developmental variations between the control and treated groups.
Key result
Dose descriptor:
NOAEC
Effect level:
>= 88.6 ppm (analytical)
Based on:
test mat.
Remarks on result:
not determinable due to absence of adverse toxic effects
Abnormalities:
no effects observed
Developmental effects observed:
no
Conclusions:
Treatment with t-dodecyl mercaptan by whole body inhalation at an actual exposure level of 88.6 ppm or less did not produce a teratogenic effect in rats.
Executive summary:

In a study comparable to OECD 414 guideline, pregnant Charles River COBS®CD® rats, randomly assigned to one control group and two t-dodecyl mercaptan treated groups of 25 animals, were used to determine the teratogenic potential of t-dodecyl mercaptan. Mean actual exposure levels of 22.7 and 88.6 ppm, which corresponded to desired exposure levels of 25 and 100 ppm, were administered by whole body inhalation exposure on gestation days 6 through 19 on a 6-hour daily exposure schedule. The control group was exposed to filtered air only on a comparable regimen. Cesarean sections were performed on all surviving rats on gestation day 20 and fetuses removed for teratologic evaluation.

One rat died at 100 ppm. The cause of death could not be determined. Survival was 100% in the control rats and the 25 ppm group. There were no biologically meaningful or relevant statistically significant differences in the mean number of total implantations, corpora lutes and fetal body weight or in the fetal sex distribution in all Cesarean section observations when compared to the control values. No adverse treatment-related or statistically significant differences in the incidence of fetal malformations when compared to those of the control group. Dose-related decreases in mean maternal body weight gain occurred in the t-dodecyl mercaptan treated rats. There were no meaningful differences in the appearance, behavior and necropsy when compared to those of the control group. Treatment with t-dodecyl mercaptan by whole body inhalation at an actual exposure level of 88.6 ppm or less did not produce a teratogenic effect in rats.

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Meets generally accepted scientific standards, well documented and acceptable for assessment
Qualifier:
equivalent or similar to
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Deviations:
yes
Remarks:
only two concentration tested
GLP compliance:
yes
Limit test:
no
Species:
mouse
Strain:
CD-1
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Charles River Breeding Laboratories, Inc., Portage, Michigan
- Age at study initiation: 12 weeks old
- Weight at study initiation: 24-33 grams on gestation day 0
- Fasting period before study: no
- Housing: individually in hanging wire-mesh cages, nn gestation day 6 animals were transferred to stainless steel and glass exposure chambers
- Diet (ad libitum, except during the exposure period ): Purina® Certified Rodent Chow® #5002
- Water (ad libitum, except during the exposure period): tap water
- Acclimation period: 14 day

ENVIRONMENTAL CONDITIONS
- Temperature (°F): 76-85 (exposure chambers)
- Humidity (%): 35-41 (exposure chambers)
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12
Route of administration:
inhalation: vapour
Type of inhalation exposure (if applicable):
whole body
Vehicle:
air
Details on exposure:
GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: stainless steel and glass exposure chambers with a volume of one cubic meter
- Method of holding animals in test chamber: individually in hanging wire-mesh cages
- System of generating vapor: Vapor atmospheres of t-dodecyl mercaptan (TDM) were generated by one of two methods. The first method was used to generate the 25 ppm group atmosphere. With this system a syringe-drive pump (Sage model 355) delivered the test materiai at a known, constant rate to the top of a 19.6 cm high column filled with 5 mm diameter glass beads. Air heated by a 400 watt cartridge heater passed up the bead column counter-current to the liquid flow. Vaporization occurred within the bead column. The vapors were then piped to the air inlet of the exposure chamber where dilution with chamber ventilation air (approximately 250 L/min) reduced the concentration to the desired level. Heat tape was wrapped around the trap to prevent condensation. The current supplied to both the cartridge heater and the heat tape was controlled individually by variable autotransformers.
The TDM concentration for the 100 ppm group was generated with a second method of vapor generation. With this system all of the chamber ventilation air was passed through an atomization chamber which had been charged with a known amount of test material. An FMI laboratory pump was then used to deliver the test material to an atomizer (Spraying Systems, No. 1650 liquid nozzle, No. 64 air nozzle). The atomization step served to greatly increase the surface area of the test material which increased, in turn, the vaporization rate to obtain a relatively high vapor concentration of test material. Glass wool was placed in the exit pipe of the atomization chamber to prevent aerosol from passing into the exposure chamber. To overcome the resistance of the glass wool filter, the exposure chamber was operated at a negative pressure of approximately 0.2 - 0.4 inches of vater.
- Temperature, humidity, pressure in air chamber: 76-85 °F, 35-41%
- Air flow rate: no data
- Air change rate: no data
- Method of particle size determination: Since the generation method for the 100 ppm group vapor level involved an atomization step, samples were collected to determine the amount of aerosol in the chamber atmosphere. Samples were collected on 25 mm glass fiber filters at a rate of 1 L/min for 30 minutes. The filters were placed in 2 ml of n-hexane to extract the collected TDM and 2 pl of the resultant solution were injected into the GC. Two injections were made of each of 4 filter samples. Three concurrent vapor samples were collected for each filter sample. During the experiment the vapor phase concentration averaged 53 ppm while the samples of recovered aerosol averaged 0.18 ppm. From these data we concluded that aerosol would not constitute an appreciable fraction of the total TDM concentration in the vapor exposure atmosphere.
- Treatment of exhaust air: no data

TEST ATMOSPHERE
- Brief description of analytical method used: The actual vapor concentration of TDM in the chamber atmosphere was determined by a gas chromatograph fitted with a gas sampling valve and sample loop. The GC was connected to a Hewlett-Packard Model 3388A integrator for data collection and reduction and was calibrated with liquid-phase standards of TDM in n-hexane.
- Samples taken from breathing zone: yes
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
see above
Details on mating procedure:
At the end of the acclimation period, all animals were weighed and subjected to a detailed physical examination. At this time, animals considered suitable for study were cohabitated with stock males utilized exclusively for this purpose.
One female and one male animal were placed together for mating. The occurrence of copulation was determined by daily inspection for a copulatory plug or vaginal smear for sperm. The day evidence of mating was detected was
designated day 0 of gestation and the female was returned to an individual cage, assigned a permanent animal number and properly identified by ear-tag.
Duration of treatment / exposure:
G6 to G19
Frequency of treatment:
6 hours/day
Duration of test:
up to gestation day 17
Dose / conc.:
22.7 ppm (analytical)
Remarks:
Target conc.: 25 ppm
Dose / conc.:
88.6 ppm (analytical)
Remarks:
Target conc.: 100 ppm
No. of animals per sex per dose:
25
Control animals:
yes, sham-exposed
Details on study design:
- Dose selection rationale: no data
- Rationale for animal assignment (if not random): Mated females were consecutively assigned in a block design to one control group and two t-dodecyl mercaptan treated groups of 25 mice each. The order in which the mated females were assigned corresponded to the day the copulatory plug was observed and the order in which the animal appeared on the breeding record. The first mated female on the breeding record was assigned to the first group. The second mated female was assigned to the next group. Animals were assigned in this manner until the required number of mated females had been placed into each group.
Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Prior to treatment, the females were observed twice daily for mortality and overt changes in appearance and behavior. They were observed twice daily for mortality and once daily for clinical signs of toxicity from gestation day 6 through sacrifice. Females not surviving to the scheduled sacrifice were necropsied in an attempt to determine the cause of death.

DETAILED CLINICAL OBSERVATIONS: No

BODY WEIGHT: Yes
- Time schedule for examinations: gestation days 0, 6, 9, 12, 15, and 17

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): No

POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: On gestation day 20 all surviving dams were sacrificed by carbon dioxine inhalation. The abdominal and thoracic cavities and organs of the dams were examined for grossly evident morphological changes and the carcasses discarded.
Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: number and location of viable and nonviable fetuses
Fetal examinations:
All fetuses were individually weighed and examined for external malformations and variations, including the palate and eyes. Each fetus was externally sexed and individually numbered and tagged for identification. Approximately one-third of the fetuses were placed in Bouin's fixative for subsequent visceral examination by razor-blade sectioning as described by Wilson. The remaining two-thirds of the fetuses were fixed in alcohol, macerated in potassium hydroxide and stained with Alizarin Red S by a method similar to that described by Dawson for subsequent skeletal examination.
Statistics:
The male to female fetal sex distribution and the number of litters with malformations were compared using the Chi-square test criterion with Yates' correction for 2 x 2 contingency tables and/or Fisher's exact probability test as described by Siegel to judge significance of differences.
The number of early and late resorptions, nonviable fetuses and postimplantation loss were compared by the Mann-Whitney U-test as described by Siegel and Weil to judge significance of differences.
The mean number of viable fetuses, total implantations, corpora lutes and mean fetal body weights were compared by analysis of variance (one-way classification), Bartlett's test for homogeneity of variances and the appropriate t-test (for equai or unequal variances) as described by Steel and Torrie using Dunnett's multiple comparison tables to judge significance ot differences.
Clinical signs:
no effects observed
Description (incidence and severity):
The surviving mice in the control and t-dodecyl mercaptan treated group were similar in appearance, behavior, and necropsy findings.
Dermal irritation (if dermal study):
not examined
Mortality:
mortality observed, non-treatment-related
Description (incidence):
Survival was 100% in the control group and the 100 ppm group. In the 25 ppm group, one mouse died on gestation day 13. Prior to death thinness, an unkempt haircoat and ptosis of the eyelid were observed in this female. At necropsy no gross lesions were evident and the cause of death could not be determined; there was also whole litter resorption.
Body weight and weight changes:
effects observed, non-treatment-related
Description (incidence and severity):
There was a decrease in the mean maternal body weight gain of the 25 ppm group mice when compared to that of mice in the control group over the entire exposure period (gestation days 6-17) and over the entire gestation period (gestation days 0-17). No comparable decrease occurred in the 100 ppm group mice at these intervals (Table 2).
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
not examined
Gross pathological findings:
no effects observed
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined
Other effects:
not specified
Number of abortions:
effects observed, non-treatment-related
Description (incidence and severity):
One female in the 100 ppm group delivered twelve fetuses on gestation day 16. Two additional fetuses were retained in the uterus. Antemortem findings included unkempt haircoat; red matter on the limbs, abdomen, anogenital area and tail; and a moribund appearance. No gross lesions were noted at necropsy and all fetuses were externally normal.
Pre- and post-implantation loss:
effects observed, treatment-related
Description (incidence and severity):
There was a slight increase in the mean postimplantation loss and a corresponding decrease in the mean number of viable fetuses in the treated groups when compared to those of the control group. In addition, the mean postimplantation loss in the treated groups was slightly increased in comparison to the high value in the historical control data (Table 4).
Total litter losses by resorption:
effects observed, non-treatment-related
Description (incidence and severity):
Five dams each in the 25 and 100 ppm groups and three dams in the control group had whole litter resorption.
Early or late resorptions:
effects observed, non-treatment-related
Description (incidence and severity):
In the 25 ppm group there was a statistically significant increase in the mean number of early resorptions when compared to the control value; however, no statistically significant differences in the remaining components of postimplantation loss (the mean number of nonviable fetuses and the number of late resorptions) or in the mean postimplantation loss were observed. Similarly, there were no statistically significant differences in mean postimplantation loss or its composent parameters in the 100 ppm group.
Dead fetuses:
no effects observed
Description (incidence and severity):
The decreases in the mean number of viable fetuses in the treated groups were not statistically significant.
Changes in pregnancy duration:
not examined
Description (incidence and severity):
Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not examined
Changes in number of pregnant:
no effects observed
Other effects:
no effects observed
Description (incidence and severity):
There were no treatment-related or statistically significant differences in the mean number of corpora lutea or the mean implantations in treated groups when compared to those of the control group.
Key result
Dose descriptor:
LOAEC
Effect level:
22.7 ppm (analytical)
Based on:
test mat.
Basis for effect level:
pre and post implantation loss
Abnormalities:
effects observed, treatment-related
Description (incidence and severity):
increase in post-implatation loss
Fetal body weight changes:
effects observed, non-treatment-related
Description (incidence and severity):
There was a statistically significant decrease in mean fetal body weight in the 25 ppm group when compared to that of the control group. The difference from the control group was less than 10%. The mean fetal body weight in the 25 ppm group was similar to the mean value in the historical control data. In the 100 ppm group, the mean fetal body weight was comparable to the control value and the historical control data; no statistically significant difference from the control group was noted.
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not examined
Reduction in number of live offspring:
not examined
Changes in sex ratio:
no effects observed
Changes in litter size and weights:
not examined
Changes in postnatal survival:
not examined
External malformations:
no effects observed
Skeletal malformations:
no effects observed
Visceral malformations:
no effects observed
Other effects:
not specified
Details on embryotoxic / teratogenic effects:
The incidence of litters with fetal malformations was reduced in the 100 ppm group in comparison to that of the control group, while in the 25 ppm group the occurrence of fetal malformations in litters was comparable to the control value. No statistically significant differences were noted. Forked cervical arches occurred in 10 fetuses distributed among six litters in the control group, and in three fetuses each distributed among two litters each in 25 and 100 ppm group. In the 25 ppm group, four fetuses distributed among two litters had cleft palate; this malformation was present as single instances in the control group and in the 100 ppm group. The remaining malformations observed in the control and/or treated group mice were present in one or two fetuses in one or two litters.
No biologically meaningful differences in the incidence of genetic and developmental variations were observed in the fetuses in the treated groups when compared to the control values.

Key result
Dose descriptor:
NOAEL
Effect level:
>= 88.6 ppm (analytical)
Based on:
test mat.
Remarks on result:
not determinable due to absence of adverse toxic effects
Abnormalities:
no effects observed
Key result
Developmental effects observed:
no
Conclusions:
Treatment with t-dodecyl mercaptan by whole body inhalation at an actual exposure level of 88.6 ppm or less did not produce a teratogenic effect in mice.
Executive summary:

In a study comparable to OECD 414 guideline, pregnant Charles River CD®-1 mice, randomly assigned to one control group and two t-dodecyl mercaptan treated groups of 25 animals each, were used to determine the developmental toxicity/teratogenic potential of t-dodecyl mercaptan. Mean actual exposure levels of 22.7 and 88.6 ppm, which corresponded to desired exposure levels of 25 and 100 ppm, were administered by whole body inhalation exposure on gestation days 6 through 16 on a 6-hour daily exposure schedule. The control group was exposed to filtered air only on a comparable regimen. Cesarean sections were performed on all surviving mice on gestation day 17 and fetuses removed for teratologic evaluation.

One mouse died at 25 ppm. The cause of death could not be determined. Survival was 100% in the control and the 100 ppm groups. One mouse delivered prematurely at 100 ppm. There was a slight treatment-related increase in mean postimplantation loss, reflective of a slightly increased occurrence of whole litter resorption, and, correspondingly, a slight reduction in the mean number of viable fetuses in the t-dodecyl mercaptan treated mice when compared to these of the control group mice. There were no biologically meaningful or relevant statistically significant differences in the mean number of total implantations, corpora lutes and fetal body weight or in the fetal sex distribution in the mice in the t-dodecyl mercaptan treated groups when compared to the control values. No adverse treatment-related or statistically significant differences in the incidence of fetal malformations occurred in the t-dodecyl mercaptan treated mice when compared to those of the control group. There were no meaningful differences in maternal weight gain of the t-dodecyl mercaptan treated mice or the appearance, behavior and necropsy findings of the t-dodecyl mercaptan treated mice when compared to those of the control group.

Treatment with t-dodecyl mercaptan by whole body inhalation at an actual exposure level of 88.6 ppm or less did not produce a teratogenic effect in mice.

Effect on developmental toxicity: via oral route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEC
733 mg/m³
Study duration:
subacute
Species:
rat
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available

Toxicity to reproduction: other studies

Additional information

In a 90-day inhalation toxicity study in rats (van Triel, 2017) and 28-day repeated inhalation toxicity studies in rats, mice and dogs (Ulrich, 1985), no histological effect was observed on the reproductive organs and the sperm parameters.

Justification for classification or non-classification

No Classification for reproductive toxicity according to the available data and CLP/GHS criteria.